INDV — Indivior Pharmaceuticals, Inc.
NASDAQ | Sector: Pharmaceuticals | Data as of 2026-07-30 07:12:30 UTC | ESEN Master AI Score (V3.5-Live)
| Metric / Component | Grade | Score | Evidence & Rationale | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B− | 72 | Pharmaceutical pure-play with strong 52W momentum (+132%) offset by elevated current valuation (P/E 23.28) and weak profitability signals. Forward P/E compression (13.53) suggests market pricing moderate near-term growth. Hyper-growth flag present; low beta (0.53) indicates defensive positioning. | 6−12M |
| SA Quality/Value Composite | C+ | 65 | P/E 23.28 v. forward 13.53 indicates near-term derating or EPS lift expected. Hyper-growth flag present despite weak profitability metrics. Revenue growth YoY of +10.34% supports growth narrative but EPS growth YoY data unavailable, limiting visibility into earnings quality. | 3−6M |
| Zacks Earnings Momentum | B | 75 | YoY revenue growth of +10.34% is solid for pharma. Forward P/E (13.53) discount to trailing (23.28) implies analyst expectations of earnings acceleration or multiple compression. EPS YoY growth data not disclosed; assessment constrained. 52W return of +132% reflects strong momentum cycle. | 3−6M |
| Institutional & Smart Money Flow | B− | 68 | Strong 52W performance (+132%) attracts institutional capital. Low beta (0.53) suggests defensive, mature positioning relative to broader market. Market cap of $4.89B indicates mid-cap liquidity. Average volume (1.56M shares) moderate. Recent −2.17% daily pullback may signal profit-taking after strong run. | 1−3M |
| Growth Sustainability & Moat | C | 62 | Hyper-growth flag present but "strong profitability" flag is FALSE—critical gap. Pharmaceuticals typically require durable IP moats and margin expansion; current metrics do not confirm this. Revenue growth of +10.34% is moderate for "hyper-growth" designation. Limited visibility on pipeline, patent expirations, or competitive positioning. | 6−12M |
| Valuation & Safety (Pre-Penalty) | C+ | 64 | Current P/E of 23.28 is elevated relative to pharma sector median (~15−18). Forward P/E of 13.53 is fair to attractive, implying significant near-term compression or earnings inflection priced in. 52W range ($16.99 low, $42.81 high) shows 152% swing; current price near 52W high risks mean reversion. No dividend yield disclosed. | 3−6M |
| Penalty Overlay | −8 | −8 | Weak profitability flag (no dividend, earnings data gaps, no forward guidance visibility). Elevated current valuation relative to historical range and peer benchmarks. Earnings date and analyst target price not disclosed. Data gaps on earnings and earnings date limit near-term catalyst visibility. | 0−3M |
| Confidence Score | C+ | 66 | Strong price and metric data (current snapshot complete). Data gaps on earnings date, analyst consensus, and eps_growth_yoy limit forward predictability. Coverage constrained by missing qualitative factors (management, pipeline, regulatory backdrop). Assessment based on disclosed quantitative metrics only. | 6−12M |
| Volatility & Drawdown Risk | B+ | 78 | Beta of 0.53 indicates LOW systematic volatility—below-market sensitivity. Recent 52W run from $16.99 to $42.81 demonstrates high absolute swings. Current pullback (−2.17% today) is minor; however, proximity to 52W high ($42.81) suggests elevated reversion risk if momentum breaks. Defensive beta is favorable for downside protection. | 1−3M |
| Crowding Risk Flag | ELEVATED | −12 | Strong 52W performance (+132%) attracts retail and momentum capital. Current price near 52W high signals potential crowding. Hyper-growth flag without corresponding profitability may indicate sentiment-driven valuation. Forward P/E compression (13.53 v. 23.28 trailing) prices in aggressive derating or earnings relief. Recommend caution on entry near current levels. | 1−3M |
Indivior operates in the pharmaceutical sector, a defensive, capital-intensive industry characterized by high barriers to entry (IP, regulatory) and long development cycles. Peer set includes larger-cap pure-plays (e.g., Viatris, Allergan, smaller specialty pharma names). INDV's $4.89B market cap positions it as a mid-cap player. The P/E of 23.28 is materially higher than most traditional pharma peers (sector median ~16−18), suggesting the market is pricing a growth or turnaround narrative. The forward P/E of 13.53—a 42% discount to trailing—is unusual and warrants scrutiny: either (A) the market expects significant near-term earnings growth, or (B) forward earnings estimates are conservative/temporary. Low beta (0.53) is typical of mature, cash-generative pharma names. The hyper-growth flag is inconsistent with the moderate revenue growth (+10.34% YoY), suggesting either a recent inflection event or classification lag in data sources.
INDV is in a consolidation phase following a 132% 52W rally. The −2.17% pullback today is minor profit-taking. Near-term technicals suggest elevated crowding risk at 52W highs ($42.81 vs. current $40.10). Institutional demand is present (low beta, large market cap), but retail/momentum capital may face headwinds if earnings miss or macro sentiment shifts. Catalysts: earnings announcement (date TBD), analyst upgrades/downgrades, sector rotation. Recommendation: Hold/accumulate on dips below $38; reduce if breaks above $42.50 without earnings catalyst.
Medium-term trajectory hinges on whether the forward P/E compression (13.53) is justified by EPS acceleration or is a multiple-reduction mirage. If revenue growth of +10.34% sustains and converts to double-digit EPS growth, INDV could re-rate toward P/E 18−20 (fair value for pharma growth). If profitability stalls or guidance is slashed, reversion to P/E 15−16 is possible, implying 25−30% downside. The hyper-growth flag and weak profitability signal a company in transition; management execution and pipeline clarity are critical. Longer-term risk: patent cliff, competitive generics, regulatory headwinds. Recommendation: Wait for earnings clarity and guidance before large position size.
INDV (Indivior Pharmaceuticals) — HOLD with Caution; Elevated Valuation + Growth Uncertainty. The stock has delivered exceptional 52W momentum (+132%) and is supported by low systematic volatility (beta 0.53), making it attractive to defensive/income-oriented funds. However, current trailing P/E of 23.28 is elevated for a pharmaceutical name with moderate revenue growth (+10.34%) and unconfirmed profitability. The forward P/E compression to 13.53 prices in significant near-term EPS relief or derating; this is a key risk if earnings disappoint. Crowding risk is elevated near 52W highs. Recommend entry on pullbacks ($36−$38 range) or await earnings clarity. Confidence in this score is moderate (66/100) due to data gaps on earnings date, analyst consensus, and eps growth trajectory.
Grade: B− | Horizon: 6−12 Months | Risk Level: Moderate-High (Crowding + Valuation)
INDV Stock Analysis & Forecast
Is INDV a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
INDV Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, INDV shows balanced risk-reward characteristics.
Should You Buy INDV Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in INDV.